3 news items
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SEEL
16 May 24
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
SEEL
14 May 24
, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
SEEL
19 Mar 24
Litigation Reform Act of 1995. These statements include, among others, those regarding the Phase 2/3 study of SLS-005, statements regarding
- Prev
- 1
- Next